MECOM rearrangement involving the MYC locus: Two additional patients with the rare translocation, t(3;8)(q26.2;q24), and molecular review.
MECOM rearrangement
MYC rearrangement
Myeloid neoplasms
t(3;8)(q26.2;q24)
Journal
Leukemia research
ISSN: 1873-5835
Titre abrégé: Leuk Res
Pays: England
ID NLM: 7706787
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
04
05
2020
revised:
18
05
2020
accepted:
19
05
2020
pubmed:
15
6
2020
medline:
5
11
2020
entrez:
15
6
2020
Statut:
ppublish
Résumé
A relatively small subset of myeloid neoplasms involve rearrangements of cytoband 3q26.2. Such rearrangements are often in response to therapy and carry a poor prognosis. The ectopic expression of MECOM is the result of such translocations. To date, thirty-three t(3;8)(q26.2;q24) cases have been reported; we contribute two patients with confirmed MECOM and MYC rearrangements. Both patients presented with pancytopenia and were diagnosed with myelodysplastic/myeloproliferative disorders. In addition to translocation t(3;8), Patient 1 possessed a derivative chromosome 5, while Patient 2 possessed monosomy 7; neither patient's clonal abnormalities resolved in follow-up studies. Of the previous 33 cases, one exhibited 5q loss, while monosomy 7 was found in fifteen. These findings contribute to the small number of reported cases with t(3;8) translocations. We also speculate about the molecular mechanisms associated with this translocation.
Identifiants
pubmed: 32535247
pii: S0145-2126(20)30092-8
doi: 10.1016/j.leukres.2020.106387
pii:
doi:
Substances chimiques
MDS1 and EVI1 Complex Locus Protein
0
MECOM protein, human
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106387Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest All contributors have read and approved this submission; there are no conflicts of interest to declare.